Oct 9

21m 44s

Making money in biotech stocks

About this episode

How to trade and invest in the biotech space with ROTY Biotech Community's Jonathan Faison (0:35). Making money in biotech (5:40). Managing sector risk (9:20). Geron - a stock he never thought he'd own (17:10).

Show Notes:
Finding Winners In Biotech, Probably The Riskiest Sector
Syndax Pharmaceuticals: A Tale Of Two Drug Launches
Arcutis Biotherapeutics: Another Approval Under Their Belt

Episode transcripts

For full access to analyst ratings, stock and ETF quant scores, and dividend grades, subscribe to Seeking Alpha Premium at seekingalpha.com/subscriptions

Up next

Today

Contrarian plays and real asset opportunities from next gen investors

Rob Isbitts checks in with analysts <a href="https://seekingalpha.com/author/julia-ostian?source=ie_podcast:contrarian_plays" target="_blank" rel="noreferrer noopener">Julia Ostian</a>, <a href="https://seekingalpha.com/author/jack-bowman?source=ie_podcast:contrarian_plays" targe ... Show More

33m 36s

Nov 23

Steven Cress' 6 picks: 3 dividend income, 3 AI growth stocks

Steve Cress, our head of <a href="https://seekingalpha.com/author/steven-cress-quant-team?source=ie_podcast:6_picks" target="_blank" rel="noreferrer noopener">Quant</a> at Seeking Alpha, on the power of quant (0:45). Barbell approach in times of market volatility (6:25). 3 divide ... Show More

42m 14s

Nov 20

REITs are boring and boring is good

Hoya Capital's <a href="https://seekingalpha.com/author/hoya-capital/analysis?source=ie_podcast:reits_are_boring" target="_blank" rel="noreferrer noopener">David Auerbach</a> on past REIT underperformance evolving into solid fundamentals across the board (1:00). Interest rates an ... Show More

40m 40s

Recommended Episodes

Sep 9

How Dr. Josep Bassaganya-Riera IPO'd Landos & Sold It to AbbVie for $200M+ and … and Is Doing It Again with NImmune

From Barcelona to Wall Street — Dr. Josep Bassaganya-Riera’s journey is nothing short of extraordinary. A veterinarian-turned-immunologist, he went on to found multiple biotech companies, take Landos Biopharma public, and lead one of the only private biotech firms with a Phase 3 ... Show More

28m 22s

Nov 2024

It pays to be a bull

Gary Vaughan from Daily Stock Picks highlights ETFs and why setting your risk tolerance as investor is important (0:10). How the macro picture affects his portfolio performance (1:10). Tech earnings: Apple's valuation is concerning, Google monetizing AI, but is Microsoft? High fl ... Show More

8m 15s

Feb 2025

Cannabis REITs: less risky choices in a risky sector

Julian Lin updates his views on cannabis REITs IIPR and NewLake Capital (1:15). RIP Cannabis Growth Investor - changed thesis on cannabis MSOs (6:45). Why Green Thumb has done well relative to the sector (13:35). Episode transcripts Show Notes: NewLake Capital: 9.3% Dividend Yiel ... Show More

19 m

Oct 2024

8 Dividend Stocks You Can't Ignore in 2025

Welcome back to another insightful episode of Market Mondays! 💼 In this installment, Rashad Bilal and Ian Dunlap dive deep into eight dividend stocks that should be on your radar as we move through 2025. 🎯 Timestamps:<a href= ... Show More

9m 32s

Nov 2024

Crypto stocks mining gains premarket

Biggest stock movers Monday: Crypto stocks and TSLA. (00:25) McKesson (MCK), Oracle (ORCL) among finalists to acquire Veradigm: report. (01:10) Smith & Nephew (SNN) investors may push for breakup - Mail on Sunday. (02:10) Episode transcripts seekingalpha.com/wsb. Show links: Ear ... Show More

5m 25s

Sep 2024

Episode 215: 1 Small Cap Biotech (TWST) Stock to Buy Now? Chip Stocks Are the Best Show In Town

Check out the New Bond account with an initial APY of 6.9%, only at <a href="https://public.com/csi" target="_blank" rel="noopener noreferer">https://public.com/csi</a> We are discussing Twist Bioscience (TWST), a fascinating biotech company that helped revolutionize DNA synt ... Show More

20m 46s

Apr 2025

Aswath Damodaran, Investing in Uncertainty

Compared to Turkey, the United States is an ocean of stability. Aswath Damodaran teaches corporate finance and valuation at the Stern School of Business at New York University. Motley Fool Senior Analyst Matt Argersinger caught up with Damodaran for our Market Playbook Summit. T ... Show More

35m 50s

Apr 2025

Have cannabis investors been early or wrong or both?

Cannabis expert Jesse Redmond shares why he's now at LEEF Brands (1:30). Excited about New York's evolution (8:15). How and why it got so bad in the industry (16:00). Are we early or are we wrong? (22:05) Who may survive and get to the finish line (28:35). Intoxicating hemp marke ... Show More

48m 21s

Jul 2024

Ether ETFs dip on first day

Spot ether ETFs close out first trading day lower as ether price slips. (00:27) Tesla (TSLA) earnings call: Elon Musk talks robotaxi delay, energy upside, discounting downside, and calls out Nvidia. (02:03) CrowdStrike (CRWD) blames bug in content update for global Windows meltdo ... Show More

5m 55s

Jun 2023

Is Now the Time to Buy Dividend-Paying Stocks? (ft. BBAE’s James Early)

Investors love dividends. There's something special about receiving cold hard cash into your brokerage account every quarter, which you can use to pay for expenses or reinvest and buy more stock. Over time, reinvesting dividends can compound your returns. But how do ... Show More

23m 49s

Listen to millions of songs and podcasts on Anghami